BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16733218)

  • 21. Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations.
    Katayama Y; Kawai S; Miyagawa-Hayashino A; Takemura Y
    Respirol Case Rep; 2019 Aug; 7(6):e00434. PubMed ID: 31139414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
    Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
    Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
    Garon EB; Siegfried JM; Stabile LP; Young PA; Marquez-Garban DC; Park DJ; Patel R; Hu EH; Sadeghi S; Parikh RJ; Reckamp KL; Adams B; Elashoff RM; Elashoff D; Grogan T; Wang HJ; Dacic S; Brennan M; Valdes Y; Davenport S; Dubinett SM; Press MF; Slamon DJ; Pietras RJ
    Lung Cancer; 2018 Sep; 123():91-98. PubMed ID: 30089602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.
    Telesco SE; Shih A; Liu Y; Radhakrishnan R
    Cancer Res J; 2011; 4(4):1-35. PubMed ID: 25346782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
    Telesco SE; Vadigepalli R; Radhakrishnan R
    Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.
    Angulo B; Conde E; Suárez-Gauthier A; Plaza C; Martínez R; Redondo P; Izquierdo E; Rubio-Viqueira B; Paz-Ares L; Hidalgo M; López-Ríos F
    PLoS One; 2012; 7(8):e43842. PubMed ID: 22952784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
    Rexer BN; Arteaga CL
    Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is high resolution melting analysis (HRMA) accurate for detection of human disease-associated mutations? A meta analysis.
    Li BS; Wang XY; Ma FL; Jiang B; Song XX; Xu AG
    PLoS One; 2011; 6(12):e28078. PubMed ID: 22194806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
    Elferink LA; Resto VA
    J Signal Transduct; 2011; 2011():982879. PubMed ID: 21776391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
    Teng YH; Tan WJ; Thike AA; Cheok PY; Tse GM; Wong NS; Yip GW; Bay BH; Tan PH
    Breast Cancer Res; 2011 Apr; 13(2):R35. PubMed ID: 21457545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.
    Ridd K; Bastian BC
    J Invest Dermatol; 2010 Mar; 130(3):901-3. PubMed ID: 19812598
    [No Abstract]   [Full Text] [Related]  

  • 35. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.
    Telesco SE; Radhakrishnan R
    Biophys J; 2009 Mar; 96(6):2321-34. PubMed ID: 19289058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
    Pichler M; Balic M; Stadelmeyer E; Ausch C; Wild M; Guelly C; Bauernhofer T; Samonigg H; Hoefler G; Dandachi N
    J Mol Diagn; 2009 Mar; 11(2):140-7. PubMed ID: 19213871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer.
    Willmore-Payne C; Holden JA; Wittwer CT; Layfield LJ
    J Biomol Tech; 2008 Jul; 19(3):217-24. PubMed ID: 19137110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
    Rexer BN; Engelman JA; Arteaga CL
    Cell Cycle; 2009 Jan; 8(1):18-22. PubMed ID: 19106609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
    BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High resolution melting for mutation scanning of TP53 exons 5-8.
    Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
    BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.